Core Viewpoint - Anteris Technologies Global Corp. is actively participating in two major healthcare conferences, showcasing its commitment to advancing medical devices for heart function restoration [1][4]. Group 1: Conference Details - Anteris will present at the TD Cowen 46th Annual Healthcare Conference on March 2, 2026, featuring a fireside chat with analyst Joshua Jennings [2]. - The Barclays 28th Annual Healthcare Conference will take place on March 10, 2026, with a fireside chat led by analyst Matt Miksic [3]. - Both conferences will include 1x1 meetings and will be accessible via webcasts, which will be archived for up to 90 days [2][3]. Group 2: Company Overview - Anteris Technologies is a global structural heart company focused on designing and commercializing innovative medical devices [4]. - The company is headquartered in Australia and has a significant operational presence in Minneapolis, USA, emphasizing a science-driven approach [4]. - Anteris' lead product, the DurAVR Transcatheter Heart Valve, is designed to treat aortic stenosis and is the first biomimetic valve, aiming to replicate normal aortic blood flow [5].

Core Viewpoint - Comstock Inc. has opened a new facility in California for recycling end-of-life solar panels, receiving certification from the Department of Toxic Substances Control, positioning itself as a leader in environmentally responsible solar panel recycling in North America [1][2][3] Group 1: Facility and Certification - The new facility in Kings County, CA, is the only certified, zero-landfill solar recycling solution in North America, allowing California companies to recycle end-of-life photovoltaic (PV) modules [1] - The facility has been approved by California's DTSC and is now on a select list of companies authorized to treat PV modules, providing a local solution for recycling [1][2] Group 2: Market Demand and Services - As more solar panels reach the end of their useful life, there is a growing demand for compliant and environmentally responsible recycling solutions in California, Arizona, and Nevada [3] - The facility is designed to serve major utilities, developers, engineering and construction firms, installers, decommissioning contractors, and asset owners, offering a reliable option for managing environmental liabilities [3] Group 3: Strategic Positioning and Future Plans - The California facility enhances Comstock Metals' southwestern recycling network, optimizing logistics to support California's high demand for solar panel recycling [2] - The company is also preparing plans for a second integrated facility in Nevada, with final site selection expected soon, indicating ongoing expansion efforts [4]

Core Viewpoint - The request for the lifting of the suspension of all departments in Nordea Invest is initiated by Nordea Fund Management, a branch of Nordea Funds Oy, Finland [1] Group 1 - The request is formally communicated by Rasmus Eske Bruun, the branch manager of Nordea Fund Management [1]

Core Insights - Brunswick Corporation has been awarded a Gold BOSS Award, ranking fourth among the top experiential exhibits at CES 2026, highlighting its leadership in marine technology [1] - The awards recognize exhibitors who create immersive, narrative-driven brand environments that enhance technology demonstrations into memorable experiences [2] Company Achievements - Brunswick's exhibit featured innovative elements such as on-water immersion, interactive simulators, and expansive video storytelling, effectively showcasing the company's marine innovations and advanced technologies [2] - The CEO of Brunswick expressed pride in the recognition, emphasizing the company's commitment to advancing marine technology and engaging audiences through compelling storytelling [3] Product Innovations - At CES 2026, Brunswick unveiled several cutting-edge products, including the Sea Ray SLX 360 with Mercury Marine engines and Simrad displays, and the Fliteboard RACE model, showcasing synergies across its business lines [3] Company Overview - Brunswick Corporation is a leader in marine recreation, offering technology-driven solutions informed by consumer insights, and operates over 60 industry-leading brands [4] - The company has approximately 15,000 employees across 26 countries and has been recognized as one of America's Most Trusted Companies by Forbes Magazine [4]

Core Viewpoint - TOMI Environmental Solutions, Inc. has received official authorization for its Binary Ionization Technology (BIT) solution and SteraMist iHP brand of disinfection equipment from the Health and Safety Executive (HSE) in Great Britain, marking a significant step for the company's expansion in the UK market [1][2]. Group 1: Product Approval and Market Expansion - The BIT solution is now approved as a biocidal product for use in Great Britain, including England, Scotland, and Wales, under Regulation 528/2012 GB, and also received separate approval for Northern Ireland under Regulation (EU) No. 528/2012 [1][2]. - This approval allows for the BIT solution to be used in room fogging and handheld direct spray applications as a microbial disinfectant across various sectors such as healthcare, industrial, commercial, hospitality, and institutional settings [2][3]. Group 2: Efficacy and Applications - The BIT solution has established efficacy claims in Great Britain, demonstrating effectiveness against bacteria, yeast, and viruses with specific contact times ranging from 5 to 15 minutes depending on the application method [4]. - SteraMist products utilize a low percentage of Hydrogen Peroxide to create a germ-killing aerosol, suitable for a wide range of applications including hospitals, schools, and military facilities [4][5]. Group 3: Company Background and Commitment - TOMI Environmental Solutions, Inc. is a global leader in decontamination and infection prevention, focusing on indoor surface disinfection through its BIT platform, which was developed under a defense grant in collaboration with DARPA [5][6]. - The company emphasizes its commitment to providing innovative solutions that meet rigorous compliance, safety, and efficacy standards, with optimism for further approvals in the European Union [3][5].

Core Viewpoint - Eesti Energia is set to publish its 2025 financial results and interim report on 27 February, with an investor call scheduled for the same day to discuss the results [1] Group 1: Financial Results Announcement - The financial results and interim report will be released on 27 February [1] - The investor call will occur at 11:00 London time, 12:00 Frankfurt time, and 13:00 Tallinn time [1] - The presentation will be conducted in English, followed by a Q&A session [1] Group 2: Participation and Access - Participants are encouraged to submit questions in advance via email to ensure a productive Q&A session [1] - The report and presentation will be available on the Eesti Energia Investor Relations website on the morning of 27 February [1] - A recording and transcript of the call will be published on the same website after the event [1] Group 3: Contact Information - Danel Freiberg is the Head of Treasury and Financial Risk Management at Eesti Energia AS, available for further inquiries [2] - Contact details include a phone number and email address for direct communication [2]

Core Insights - Novo Nordisk announced results from the REDEFINE 4 trial, which investigated the efficacy of CagriSema compared to tirzepatide in individuals with obesity and comorbidities [1][2] Trial Overview - REDEFINE 4 was an 84-week open-label trial involving 809 participants with a mean baseline body weight of 114.2 kg [2] - The trial compared CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) to tirzepatide (15 mg), both administered once weekly [2] Weight Loss Results - Participants treated with CagriSema achieved a weight loss of 23.0% after 84 weeks, compared to 25.5% with tirzepatide [3] - When applying the treatment-regimen estimand, CagriSema resulted in a weight loss of 20.2%, while tirzepatide achieved 23.6% [3] - The trial did not meet its primary endpoint of demonstrating non-inferiority in weight loss for CagriSema compared to tirzepatide [3] Safety Profile - CagriSema exhibited a safe and well-tolerated profile, with the most common adverse events being mild to moderate gastrointestinal issues that diminished over time [4] Future Developments - Novo Nordisk is optimistic about CagriSema's potential as a first GLP-1/amylin-combination product for obesity treatment [5] - The company anticipates an FDA decision on CagriSema for weight management by late 2026, following its submission in December 2025 [5] - Upcoming trials include REDEFINE 11, expected to report data in the first half of 2027, and a higher-dose CagriSema trial planned for the second half of 2026 [5] About CagriSema - CagriSema is a once-weekly subcutaneous treatment being investigated for adults with obesity and type 2 diabetes, combining cagrilintide and semaglutide to reduce hunger and calorie intake [7] About the REDEFINE Programme - The REDEFINE programme is a phase 3 clinical development initiative that includes multiple trials assessing the efficacy and safety of CagriSema in various populations [8][9][10][11][12]

Group 1 - The Annual General Meeting of MT Højgaard Holding A/S is scheduled for Friday, March 20, 2026, at 3 pm [1] - The meeting will take place as a physical general meeting at Knud Højgaards Vej 7, 2860 Søborg, Denmark [1] - The notice includes the agenda and the full text of the proposed resolutions, which are attached [2]

Core Viewpoint - Spar Nord Bank A/S has approved a demerger plan to transfer part of its assets and liabilities to Kirstinehøj 17 A/S during the Extraordinary General Meeting held on 23 February 2026 [1]. Group 1: Company Actions - The shareholders of Spar Nord Bank A/S approved the proposal for a demerger in accordance with the published demerger plan [1]. - The demerger involves the transfer of specific assets and liabilities from Spar Nord Bank A/S to Kirstinehøj 17 A/S, CVR no. 31487900 [1]. Group 2: Meeting Details - The Extraordinary General Meeting took place on Monday, 23 February 2026 [1]. - The announcement was made to Nasdaq Copenhagen [1].

Core Viewpoint - Festi has been actively engaging in a share buyback program, increasing its ownership of own shares in accordance with regulatory frameworks [1][2]. Group 1: Share Buyback Details - In week 8 of 2026, Festi purchased a total of 195,000 own shares for 65,645,000 ISK, with individual purchases made on February 16, 17, 18, and 19, 2026 [1]. - The share prices for the purchases ranged from 333 ISK to 342 ISK per share, with the total amounts spent on each day being 24,975,000 ISK, 16,800,000 ISK, 11,970,000 ISK, and 11,900,000 ISK respectively [1]. - Prior to these purchases, Festi held 4,570,000 own shares, representing 1.46% of issued shares, and after the buyback, it now holds 4,765,000 own shares, or 1.52% of issued shares [2]. Group 2: Buyback Program Overview - The buyback program was initially announced on December 3, 2025, and aims to repurchase a total of 2,500,000 own shares, which is 0.80% of the issued shares, with a maximum purchase price cap of 825 million ISK [2]. - The execution of the buyback program complies with the Act on Public Limited Companies and relevant European regulations regarding market abuse and fraud [1].